Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
#HARPOON THERAPEUTICS PLUS#
In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 21% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. The current consensus EPS estimate is -$0.49 on $6.61 million in revenues for the coming quarter and -$3.46 on $28.84 million in revenues for the current fiscal year. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. So, the shares are expected to perform in line with the market in the near future. The poster, titled TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome (CRS) by. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. recently presented a poster with preclinical data on its TriTAC-XR T cell engager platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, DC. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for Harpoon Therapeutics, Inc. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells. What's Next for Harpoon Therapeutics, Inc. Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. Shares have lost about 40.8% since the beginning of the year versus the S&P 500's gain of 17.2%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
The company has topped consensus revenue estimates two times over the last four quarters. This compares to year-ago revenues of $2.76 million. Harpoon Therapeutics, Inc.Which belongs to the Zacks Medical - Drugs industry, posted revenues of $5.84 million for the quarter ended June 2021, missing the Zacks Consensus Estimate by 11.61%.
0 kommentar(er)
